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Inhibition of L-type and cyclic nucleotide-gated 
calcium channels demonstrates synergistic 
mechanisms for prolonging vascular contractions 
induced by a mimetic of thromboxane A2
Joseph W. Kellum
IntroductIon
Thromboxane A2 (TxA2) is 
a metabolite of arachadonic 
acid—an unsaturated membrane 
phosopholipid. TxA2 is released 
by platelets during tissue trauma 
and inflammatory events (1). This 
prostanoid signaling molecule is 
responsible for further platelet 
activation and aggregation, as well 
as constriction of smooth muscle 
comprising the walls of bronchioles 
and blood vessels (1). The current 
study examines the effects of TxA2 on 
vascular smooth muscle.
It has been shown that TxA2 
evokes vasoconstrictive responses 
that persist for a longer duration 
than a number of other vasoactive 
molecules (e.g. phenylephrine, KCl 
and others) (2). This observation is 
of clinical importance, due to the 
fact that TxA2 vascular contractions 
elicited in vivo have the potential 
to decrease blood supply to tissues 
for prolonged periods of time. 
Such circumstances could be life-
threatening in the case of TxA2 
release during acute, traumatic 
events in which decreased blood 
flow leads to reductions in nutrient 
delivery and eventual cell death, such 
as myocardial infarction or stroke (3). 
In these situations, TxA2 produced 
in response to tissue trauma would 
promote vasoconstriction, which 
would trigger a positive feedback 
cycle resulting in greater decreases 
in blood supply. Strong correlations 
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have also been observed between 
increased levels of thromboxane B2 
(a metabolite of TxA2) and patients 
suffering from angina pectoris, 
which could be considered a chronic 
manifestation of the negative effects 
of TxA2-induced vasoconstriction (4).
The primary purpose of this 
investigation was to gain a better 
understanding of the molecular 
mechanisms responsible for these 
characteristically prolonged vascular 
contractions elicited in vessels 
exposed to TxA2. Unfortunately, TxA2 
is an unstable molecule, with a 
half-life of ~30 seconds in aqueous 
solution at 37°C (5). This instability 
makes use of the endogenous 
compound impractical in the 
laboratory. For this reason, a stable 
mimetic of TxA2 (known as U-46619) 
was used to elicit the vascular 
contractions of interest throughout 
these experiments (6).
Both TxA2 and U-46619 bind 
to the TP receptor to elicit cellular 
signaling cascades, ultimately leading 
to smooth muscle contraction. The 
TP receptor is a metabotropic, G 
protein-coupled receptor. Specifically, 
the activated G protein has a Gαq 
subunit which dissociates from the βγ 
subunit and diffuses into the cytosol 
to activate phospholipase C (PLC). 
Activated PLC cleaves membrane 
phospholipid phosphatidylinositol 
4,5-bisphosphate (PIP2), producing 
inositol 1,4,5-triphosphate (IP3) and 
diacyl glycerol (DG). IP3 migrates 
to the sarcoplasmic reticulum (SR), 
where it binds to Ca2+ channels in the 
membrane of the SR. This permits 
the release of intracellular Ca2+ stores 
into the cytosol. Increases in cytosolic 
Ca2+ concentrations lead to activation 
of a number of Ca2+ dependent signal 
transduction cascades (1).
Diacyl glycerol (the portion 
of PIP2 that remains in the 
membrane) then couples with 
Ca2+ in the cytosol to activate 
protein kinase C (PKC). Activated 
PKC phosphorylates L-type Ca2+ 
channels in the plasma membrane. 
Phosphorylation, coupled with cell 
membrane depolarization, leads to 
the opening of these L-type Ca2+ 
channels, which are both voltage-
gated and ligand-gated. Opening of 
L-type Ca2+ channel permits influx 
of extracellular Ca2+, which leads to 
greater increases in intracellular Ca2+ 
concentrations. Elsewhere in the cell, 
these increases in intracellular Ca2+ 
concentration lead to the formation 
of Ca2+/calmodulin kinases, which 
activate myosin light chain kinase 
(MLCK) via phosphorylation. In 
turn, MLCK propagates the signal by 
phosphorylating myosin light chain 
(MLC). MLC then undergoes cross-
bridge cycling with actin filaments, 
thus promoting contraction of the 
smooth muscle (1).
Concurrent with the mechanism 
for contraction discussed above, 
myosin phosphatase acts to 
dephosphorylate MLC. This 
promotes return of the smooth 
muscle tissue to a relaxed state. 
Myosin phosphatase is regulated 
by a signaling cascade known as 
the Rho-kinase pathway (1). This 
cascade also begins with a G protein 
coupled to the TP receptor (7). When 
activated, this Gα subunit activates a 
membrane-bound guanine-exchange 
factor, RhoGEF, which activates 
RhoA. RhoA then activates Rho-
kinase, which phosphorylates myosin 
phosphatase. Phosphorylation of 
myosin phosphatase inactivates the 
enzyme. This shifts the contraction/
relaxation equilibrium in favor of 
the contracted state, and serves as a 
mechanism for prolonging vascular 
contraction (1).
Left is a flow chart of the signal transduction pathways 
for txa2-induced contraction in smooth muscle. here, 
it can be seen that binding of the ligand (txa2 or 
u-46619) to the tP receptor activates two separate signal 
transduction pathways. one pathway leads to increases 
in intracellular ca2+ concentrations, which promotes 
contraction. the other serves the purpose of maintaining 
established contractions. a more detailed description can 
be found in the text (1).
FIgure 1. 
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Unpublished data from this lab (8), 
as well as many published works over 
the past decade have demonstrated 
that inhibition of Rho-kinase does 
lead to significantly increased rates 
of relaxation in vessels initially 
contracted using U-46619 (9, 10, 
11). Thus, it is apparent that the 
Rho-kinase pathway is necessary in 
establishing the prolonged nature 
of the U-46619-induced vascular 
contractions. However, this pathway 
has also been shown to be activated 
by a number of other vasoactive 
agents, none of which display these 
significantly prolonged contractions 
(10, 11). Phenylephrine (PE), for 
instance, binds to an α1 adrenergic 
receptor. This receptor has been 
demonstrated to be linked to both 
the Gαq protein responsible for 
establishing the U-46619 contraction, 
as well as the Rho-kinase pathway 
(10, 11). These similarities render 
the PE contraction a reliable control 
to which the U-46619 contraction 
can be compared. The difference, 
however, is that PE-induced vascular 
contractions relax within minutes 
following removal of PE from the 
bathing solution of isolated blood 
vessels, while U-46619-induced 
contractions persist for hours 
before returning to basal tension 
(6). Therefore, another unidentified 
mechanism must play a significant 
role in prolonging U-46619-induced 
contractions.
In work published from this 
lab, inhibition of L-type Ca2+ 
channels was examined in the 
context of two different types of 
contractions (6). Under normal 
circumstances, treatment of vascular 
smooth muscle with KCl leads 
to significant contractions due to 
depolarization of the cell membrane 
potential and opening of voltage-
gated Ca2+ channels. When L-type 
Ca2+ channels were inhibited, KCl 
treatment elicited no measurable 
contractions. Inhibition of L-type 
Ca2+ channels was also effective 
in attenuating U-46619-induced 
contractions; however, the TxA2 
mimetic evoked measurable (though 
markedly reduced) contractions, 
even in the presence of these 
L-type Ca2+ channel inhibitors. The 
authors concluded that the U-46619 
contraction mechanism likely utilizes 
more than one membrane channel 
for influx of extracellular Ca2+ (6). 
More recent work, published by 
Leung et al, introduced the idea 
that cyclic nucleotide-gated (CNG) 
Ca2+ channels may play a role in the 
U-46619-induced mechanism (12). 
This conclusion led to speculation 
that CNG Ca2+ channels might 
be the extra conduits for influx of 
extracellular Ca2+ referenced in the 
earlier work by Liu et al. 
Therefore, the objective of this 
experiment was to inhibit both 
L-type (using an L-type channel 
inhibitor known as nifedipine) and 
CNG Ca2+ channels (using a CNG 
channel inhibitor known as L-cis-
diltiazem) to test whether they 
played roles—either separately, or 
in combination—in prolonging the 
TxA2/U-46619-induced contraction. 
It was hypothesized that inhibition 
of L-type and CNG Ca2+ channels 
would lead to significant increases 
in rates of relaxation in U-46619-
treated vessels. We also predicted 
that inhibition of only one channel 
at a time would lead to moderate 
increases in the observed rate of 
relaxation, while simultaneous 
inhibition of both channels would 
lead to significantly greater increases 
in rates of relaxation.
MaterIaLs and Methods
To test the effects of L-type and CNG 
Ca2+ channel inhibitors (nifedipine 
and L-cis-diltiazem, respectively) 
on U-46619-induced vascular 
contractions, segments of aorta 
were removed from euthanized 
New Zealand white rabbits (IACUC: 
AUS 42-02). Vessels were placed 
in a modified Krebs solution (6) 
and kept overnight at 40°C. All 
experiments were carried out the 
following day using a conventional 
isolated organ bath preparation. 95% 
O2/5% CO2 was bubbled through a 
physiological buffer (pH ~ 7.4), which 
was maintained at 37°C. The vessels 
were held in place by hooks, which 
applied tension in opposite directions. 
One hook was stationary, while 
the other relayed the contraction 
force created by the vessel to a force 
transducer (see figure 2 below). At 
the beginning of each experiment, a 
baseline tension of 2 grams of force 
was established to mimic the basal 
muscle tone that occurs in vivo.
this figure is a schematic of the general organ bath setup utilized to 
measure tension elicited by the vessel throughout each experiment. 
as the vessel contracted, it applied tension to the force transducer 
shown at the top of the figure. the transducer relayed the magnitude 
of the force applied at a given time to a computer, which produced a 
graph like the one seen in figure 3, below. 
FIgure 2. 
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In each experiment, six individual 
segments of the aorta were placed in 
six separate organ baths. All six baths 
were subjected to the same general 
procedure to begin each experiment. 
Following a period of equilibration, 
the organ bath was filled with 60 mM 
KCl to induce maximal contraction, 
followed by a wash in which the 
KCl solution was drained from the 
bath and fresh buffer at pH 7.4 was 
added. The vessels were then allowed 
to relax to baseline tension. This 
sequence was then repeated once 
more. Following the second wash, all 
vessels were subjected to the addition 
of 5μM U-46619 to elicit contraction. 
Once the contraction reached its peak, 
as recorded by the force transducers 
on a computerized graph (see figure 
3 above), the bath was washed for a 
third time. Following this third wash, 
the protocol varied, dependent upon 
whether inhibitors or vehicles were 
added to each bath. Figure 3 below 
has been included for the purpose 
of easily relating this protocol to the 
experiment conducted.
In the variable portion of the 
experiment, the vessels were treated 
with four different combinations 
of drugs and respective vehicles. 
The drugs used included nifedipine, 
which is an L-type Ca2+ channel 
inhibitor, at 200 μM (dissolved 
in 0.4% ethanol/99.6% water), as 
well as L-cis-diltiazem, which is 
a CNG Ca2+ channel inhibitor, at 
140 μM (dissolved in 100% water). 
These dosages were obtained from 
previously published reports in which 
dose responses were carried out to 
determine effective doses of each 
drug (6, 12). Each drug was prepared 
by first preparing a concentrated 
stock solution, which also contained 
a greater concentration of ethanol 
in the case of nifedipine. This stock 
solution was then diluted upon 
addition of a small quantity (693 μL 
for nifedipine and 450 μL for L-cis-
diltiazem) to 20 mL of physiological 
buffer in the organ bath during the 
experiment. Nifedipine and L-cis-
diltiazem were purchased from 
Enzo Life Sciences, Farmingdale, NY. 
U-46619 was purchased from Cayman 
Chemical Co., Ann Arbor, MI.
The first treatment group consisted 
of vessels treated with both inhibitors, 
namely 200 μM nifedipine, followed 
by treatment of 140 μM L-cis-
diltiazem. Following treatment, all 
vessels were allowed to relax to 
baseline tension and the relaxation 
time was recorded. The second group 
consisted of vessels treated with 200 
μM nifedipine, followed by treatment 
with L-cis-diltiazem vehicle (100% 
water). The third group consisted 
of vessels treated with nifedipine 
vehicle (0.4% ethanol/99.6% water), 
followed by treatment with 140 
μM L-cis-diltiazem. The fourth 
group consisted of vessels treated 
with nifedipine vehicle, followed 
by treatment with L-cis-diltiazem 
vehicle. This was the control set for 
this experiment. 
As stated previously, vessel 
tension was monitored electronically 
throughout the duration of the 
experiment (see figure 4A – 4D).  
At the conclusion of each experiment, 
the graphs obtained were analyzed 
to yield quantitative data in the 
form of rates of relaxation for each 
vessel. This method of data analysis 
was chosen to normalize vessels 
that varied in the magnitude of 
the contraction. These rates were 
obtained by using the following 
formula:
FIgure 3. 
Ave. Rate of Relaxation (g ⁄min) =
Magnitude of contraction (in grams)-2.00 g
______________________________________
Time required to relax to baseline (in minutes)
an example graph from a representative experiment is shown 
above. the first peak was caused by the Kcl treatments, 
respectively. the second peak is representative of the 
u-46619-induced contraction. notice how the peak caused by 
u-46619 plateaued at its maximum, whereas the Kcl-induced 
peaks began to slope downwards even before the wash. 
each treatment is marked along the x-axis, with ni and dil 
denoting nifedipine and L-cis-diltiazem, which are L-type 
and cng ca2+ channel inhibitors, respectively. the dotted 
line at 2 g of contraction signifies baseline tension, and the 
black arrow indicates the point at which the vessel returns to 
baseline tension following treatment with u-46619.
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resuLts
Computer-generated graphs 
produced during the course of an 
individual experiment are shown in 
figure 4 below. The y-axis of each 
graph displays vessel tension (grams). 
The x-axis displays time (minutes) 
throughout the duration of the 
experiment. Thus, the height of a 
line at any given point on the x-axis 
represents the force of contraction 
elicited by the vessel at that particular 
point in time.
Figures 4A – 4D display two 
different contractions: an initial KCl-
induced contraction, followed by a 
U-46619-induced contraction. This 
comparison provides good visual 
representation of the prolonged 
nature of U-46619-induced 
contractions. While contractions 
elicited using KCl relax immediately 
following removal of the high KCl 
buffer (wash), the contractions 
produced by U-46619 treatment 
persist long after the drug has been 
removed from the organ bath.
Figure 4 also facilitates qualitative 
comparison of the four different 
treatments given, and the rates 
of relaxation of each. The vessel 
represented in figure 4A was treated 
with the vehicles for each inhibitor. 
This served as the control group. It 
is obvious that the control group 
exhibited a decreased relaxation rate 
as compared to the groups treated 
with one or both inhibitors (shown in 
figures 4B – 4D). Figure 4B presents 
the responses of a vessel treated with 
both inhibitors, nifedipine and L-cis-
diltiazem. The slope of this line is 
noticeably greater than that in figure 
4A, but quite similar to the slopes 
in figures 4C and 4D, which were 
treated with L-cis-dilitiazem and 
nifedipine, respectively. This indicates 
that no significant differences were 
present between the relaxation rates 
of these three groups of inhibitor-
treated vessels.
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data representing the contractions and relaxations of four vessels are shown. the panels are 
labeled according to which drugs they received prior to the relaxation phase. notice how the 
vessels treated with various combinations of drugs reached baseline tension much more quickly 
than the vessel treated with vehicles only. on the x-axis, the treatment given at each point in time 
is indicated. ni and dil represent nifedipine and L-cis-diltiazem, respectively. also, note that the 
arrows indicate the time at which each vessel returned to baseline tension after treatment with 
u-46619. Baseline tension (2 g) is indicated by the dotted horizontal line.
FIgure 4.
Panel 4a – Both vehicles
Panel 4B – Both Inhibitors
Panel 4c – L-cis-diltiazem
Panel 4d – nifedipine
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the figure is a graphical 
representation of the mean rates 
of relaxation (g/min) for each 
treatment group of interest, with 
bars representing the standard 
error of the mean. statistical 
analysis of these data using an 
unstacked anova indicated 
that the inhibitor-treated groups 
(L-cis-diltiazem, nifedipine, and 
both inhibitors) were statistically 
synonymous (F-statistic = 1.17; 
31 degrees of freedom; P = 0.324). 
the same test, with the addition 
of the vehicle control treatment, 
indicated a strong statistical 
discrepancy between the four 
means (F-statistic = 7.61; 46 
degrees of freedom; P < 0.001).
FIgure 5. 
The mean rates of relaxation for 
all vessels within each treatment 
group are presented in figure 5. The 
control group (vehicle treatment 
only) had a significantly reduced 
mean rate of relaxation as compared 
to the three inhibitor-treated groups. 
This observation was tested using a 
one-way, unstacked ANOVA, which 
resulted in a test statistic of F = 7.61 
with 46 degrees of freedom and 
P-value < 0.001, thus, supporting 
the initial hypothesis that inhibition 
of L-type and CNG Ca2+ channels 
will lead to increases in the rates of 
relaxation in U-46619-treated vessels. 
The mean rates of relaxation for 
all vessels within each treatment 
group are presented in figure 5. The 
control group (vehicle treatment 
only) had a significantly reduced 
mean rate of relaxation as compared 
to the three inhibitor-treated groups. 
This observation was tested using a 
one-way, unstacked ANOVA, which 
resulted in a test statistic of F = 7.61 
with 46 degrees of freedom and 
P-value < 0.001, thus, supporting 
the initial hypothesis that inhibition 
of L-type and CNG Ca2+ channels 
will lead to increases in the rates of 
relaxation in U-46619-treated vessels. 
This graph also allows the mean 
rates of relaxation for the three 
inhibitor-treated groups to be 
compared. Small differences exist 
between these means, especially 
when comparing vessels treated with 
only L-cis-diltiazem to those treated 
with only nifedipine. However, 
statistical testing with a one-way, 
unstacked ANOVA in this instance 
failed to refute the null hypothesis for 
these means (F = 1.17; 31 degrees of 
freedom; P = 0.324). Therefore, these 
data indicate that no difference in 
relaxation rate is observed between 
vessels in which different Ca2+ 
channels are inhibited, as long as at 
least one channel is inhibited.
dIscussIon 
Role of L-type and CNG Ca2+ channels 
in prolonging U-46619-induced 
vascular contractions
The data obtained from these 
experiments support the hypothesis 
that inhibition of L-type and CNG 
Ca2+ channels does, indeed, lead 
to increased rates of relaxation in 
U-46619-treated vessels. The mean 
rate of relaxation for the vehicle 
(control) treatment group was 
significantly reduced in comparison 
to groups receiving nifedipine 
only, L-cis-diltiazem only, or both 
inhibitors simultaneously. However, 
the vessels treated with only one 
inhibitor—either nifedipine or 
L-cis-diltiazem—displayed rates of 
relaxation similar to vessels treated 
with both inhibitors simultaneously. 
This result was unexpected, and 
contrary to the prediction that 
inhibition of both types of Ca2+ 
channels would lead to significantly 
greater rates of relaxation than 
vessels in which only one type of 
Ca2+ channel was inhibited. While 
inconsistent with original predictions, 
this observation is equally significant. 
Thus, it was observed that inhibition 
of either set of Ca2+ channels led to 
a significant drop in the efficacy of 
the TxA2 mechanism for prolonging 
vascular contraction. We conclude that 
simultaneous, optimal functioning of 
both L-type and CNG Ca2+ channels 
is necessary in order to maintain the 
prolonged contractions characteristic 
of U-46619-treated vessels.
L-type Ca2+ channels have long 
been associated with the TxA2/U-
46619-induced contraction. These 
channels are considered to be more 
abundant in the plasma membranes 
of vascular smooth muscle cells, and 
serve as the primary source of Ca2+ 
influx (1, 6). They are also thought 
to be essential in establishing 
the initial contraction; though 
it has been shown that a small 
Means rates of relaxation
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shown is a flow chart outlining the proposed mechanism for prolonged vascular contractions 
induced by txa2/u-46619 based on the results of this experiment. here, the tP receptor is 
thought to activate another (currently unidentified) g protein, which proceeds to trigger a 
signaling cascade resulting in the opening of cng ca2+ channels. ca2+ influx through these 
channels is thought to serve a variety of mechanisms (as discussed in the text) for prolonging 
txa2-induced vascular contraction (1).
FIgure 6. 
contraction can still be obtained 
by addition of U-46619 to vessels 
pre-treated with L-type Ca2+ channel 
inhibitor, nifedipine (6). L-type 
Ca2+ channels have two different 
gating mechanisms—they are both 
voltage-dependent and dependent 
upon allosteric modification 
(phosphorylation) from protein 
kinase C (1). When the membrane is 
sufficiently depolarized, and when 
the channel is in its phosphorylated 
state, it opens to the extracellular 
environment. At this point, L-type 
channels facilitate the selective influx 
of Ca2+ ions, thereby increasing 
intracellular Ca2+ concentrations.
While the mechanism for L-type 
channel opening/closing is well 
known, the function of CNG Ca2+ 
channels remains mostly unexplored. 
These channels are known to be 
gated by cyclic nucleotides (such as 
cAMP or cGMP) in some fashion (12). 
Because cGMP is often associated 
with vascular relaxation through the 
nitric oxide (NO) pathway, it is more 
likely that cAMP is responsible for 
mediation of CNG Ca2+ channels. 
Regardless of the pathway involved, 
it has been demonstrated by this 
experiment that CNG Ca2+ channels 
are essential to prolonging U-46619-
induced vascular contractions, since 
inhibiting these channels significantly 
increases the rates of relaxation in 
aortic vessels.
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Figure 6 provides a revised 
schematic of the TxA2/U-46619 
pathway for vascular smooth muscle 
contraction. It has been modified 
to reflect the CNG Ca2+ channel-
dependent mechanism proposed 
in light of our results. For simplicity, 
the Rho-kinase pathway has been 
deleted from this diagram, although 
it remains a key component of the 
overall mechanism for prolonged 
vascular contraction.
The cascade resulting from Gαq 
protein activation is the same as 
was proposed originally. In this 
revised pathway, the TxA2 receptor 
(the TP receptor) is coupled to yet 
another G protein. Though this G 
protein has not been identified, it 
may be a Gαs subunit-containing 
protein. Activation of this G protein 
is then likely to lead to activation of 
either guanylate cyclase or adenylate 
cyclase. The latter is more likely, 
due to the cGMP mechanisms 
discussed earlier. At this point, the 
cyclic nucleotides responsible for 
regulating the opening of the CNG 
Ca2+ channels are produced. These 
second messengers lead to further 
modification of other cellular proteins, 
which ultimately lead to an allosteric 
modification of CNG Ca2+ channels, 
promoting the open state.
Once open, the CNG Ca2+ 
channels allow Ca2+ influx from 
the extracellular environment. Ca2+ 
influx through these channels in 
particular is thought to promote 
prolonged vascular contraction 
via three different mechanisms. 
The most direct effect would be a 
contribution to the formation of Ca2+/
Calmodulin kinases, which lead to 
cross-bridge cycling and promotion 
of the contracted state, as discussed 
earlier. This mechanism alone 
would explain the persistent (albeit 
diminished) nature of the contraction 
following pre-treatment with L-type 
Ca2+ channel inhibitors observed 
by Liu et al in 1997 (6). CNG Ca2+ 
channels also have the possibility of 
promoting contraction through two 
indirect means, both of which involve 
contributions to the open state of 
the more traditionally acknowledged 
L-type Ca2+ channels. 
The first indirect means involves 
the voltage-gated property of 
L-type Ca2+ channels. By acting 
as another rout for Ca2+ to enter 
the cell through the plasma 
membrane, CNG channels lead 
to a more depolarized state in the 
vicinity of the L-type channels. This 
increases the likelihood of the latter 
remaining open for longer periods 
of time. The second strategy for 
keeping the L-type channels open 
for prolonged periods involves 
Ca2+ entering through the CNG 
channels and working with diacyl 
glycerol to activate protein kinase 
C. Because this is independent from 
previously discussed mechanisms 
for PKC activation, this pathway 
can be speculated to lead to greater 
amounts of active PKC in the cell at 
any given time, thus promoting the 
phosphorylated, open state of L-type 
Ca2+ channels.
Based on this model, CNG Ca2+ 
channels are able to elicit their effects 
not only via a direct route, as is 
the case with L-type Ca2+ channels, 
but also in an indirect manner by 
promoting the open state in L-type 
channels. Therefore, we believe that 
L-type and CNG Ca2+ channels 
function in an interdependent 
fashion to elicit the prolonged 
vascular contractions characteristic of 
TxA2/U-46619-treated vessels. When 
L-type Ca2+ channels are inhibited 
by nifedipine, the primary source of 
extracellular Ca2+ has been removed 
from the equation. This eliminates 
the cooperative mechanism for 
prolonging TxA2-induced vascular 
contractions, and relaxation ensues. 
In the absence of functioning 
L-type channels, the effects of CNG 
channels are much less significant. 
On the other hand, when CNG 
Ca2+ channels are inhibited by 
L-cis-diltiazem, an equally essential 
component of the system is removed. 
Here, the cell retains its primary 
source of Ca2+ influx in the form of 
the L-type channels; however, these 
channels returned to the closed 
state much more quickly. This is 
thought to be analogous to the case 
of PE or KCl-induced contractions, 
in which CNG channels likely do 
not play a role. Thus, early L-type 
channel closure during CNG channel 
inhibition is thought to be due to lack 
of promotion of the open state by 
increased PKC activity and decreased 
membrane potential, both of which 
normally result from the increased 
Ca2+ influx provided by CNG channels.
In each case discussed, the 
interdependent, cooperative Ca2+ 
channel system for prolonged 
contraction has been eliminated 
due to inhibition of one component. 
Therefore, when both channels are 
inhibited simultaneously, the increase 
in rate of relaxation is synonymous to 
the increase observed when only one 
channel is inhibited. This is because 
individual inhibition of either 
channel has an indirect, inhibitory 
effect on the other, leaving nothing 
more to be accomplished by dual or 
simultaneous inhibition. 
LIMItatIons oF the 
Methods
This investigation has several 
limitations. It is our assumption 
that the inhibitors used in these 
experiments are exerting specific 
effects on the channels of interest 
without non-specific effects on other 
channels or intracellular signaling 
molecules. This assumption appears 
to be reasonable, based on previously 
reported data in the literature (6, 12). 
We also relied on literature sources 
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for the doses of the inhibitors used in 
these experiments. Once again, this 
seems reasonable based on previous 
investigations geared toward carefully 
obtaining dose response data as a 
means for determining appropriate 
doses for similar experimental 
preparations. 
sIgnIFIcance / cLInIcaL 
IMPLIcatIons
This study has clinical significance 
with respect to disorders in which 
tissue is damaged as a result of 
inadequate oxygen and nutrient 
supply due to decreased blood flow. 
In the chronic sense, TxA2-related 
vascular tension has been identified 
as a contributor to poor coronary 
artery circulation underlying angina 
pectoris (4). Of even greater interest 
are acute cases of vessel constriction 
resulting in myocardial infarction 
(heart attack) or stroke. In these 
circumstances, blood supply to the 
tissues in question (either cardiac 
or neural tissues, both of which 
have high requirements for oxygen, 
glucose, etc.) is decreased, resulting 
in severe tissue damage, and even 
necrosis (3). This trauma prompts 
the release of TxA2, which elicits 
powerful, prolonged vasoconstrictive 
effects that further decrease blood 
supply. Therefore, the presence of 
TxA2 in these cases induces a positive 
feedback cycle in which tissue trauma 
leads to more vasoconstriction, which 
leads to more severe tissue trauma, 
etc. By elucidating the mechanisms 
responsible for significantly 
prolonging TxA2-induced vascular 
contractions, it is possible that 
effective treatments for the inhibition 
of this phenomenon could be 
developed. Moreover, outlining 
unique components of these 
mechanisms could prove especially 
important for providing treatments 
capable of specifically targeting 
TxA2-induced vascular tension, 
thereby avoiding negative side effects 
resulting from interfering with basal 
systemic vascular tension. 
Based upon the results obtained 
in this experiment, it can be 
concluded that both L-type and 
CNG Ca2+ channels are necessary, 
but not sufficient for prolonging 
TxA2/U-46619-induced vascular 
contractions. Furthermore, following 
the logic and speculations discussed 
above, it can be concluded that 
these two types of Ca2+ channels are 
linked together in an interdependent, 
cooperative mechanism whose 
optimal functioning is necessary for 
prolonging the vascular contractions 
traditionally observed in TxA2/U-
46619-treated vessels.
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